Patents by Inventor Jennifer Golden
Jennifer Golden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11820753Abstract: Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity.Type: GrantFiled: February 10, 2021Date of Patent: November 21, 2023Assignees: Wisconsin Alumni Research Foundation, U.S. Dept. of Veterans AffairsInventors: Robert Todd Striker, Nathan Joseph Wlodarchak, John Bruce Feltenberger, Jennifer Golden
-
Publication number: 20230240940Abstract: A medical device including an application device with a first fluid path and a container movably attached to the application device. The container and the application device have a second fluid path therethrough, the container includes an inner chamber that is intermediate proximal and distal portions of the second fluid path, the inner chamber is fluidly isolated from the proximal portion of the second fluid path at a first position of the container, and the inner chamber is fluidly coupled to the proximal and distal portions of the second fluid path at a second position of the container. The first fluid path bypasses the container and the passage of fluid through the first fluid path is separately controllable from the passage of fluid through the second fluid path.Type: ApplicationFiled: April 3, 2023Publication date: August 3, 2023Applicant: Boston Scientific Scimed, Inc.Inventors: Andrew PIC, Matthew LaPLACA, Jennifer GOLDEN, Shawn RYAN
-
Patent number: 11642281Abstract: A medical device including an application device with a first fluid path and a container movably attached to the application device. The container and the application device have a second fluid path therethrough, the container includes an inner chamber that is intermediate proximal and distal portions of the second fluid path, the inner chamber is fluidly isolated from the proximal portion of the second fluid path at a first position of the container, and the inner chamber is fluidly coupled to the proximal and distal portions of the second fluid path at a second position of the container. The first fluid path bypasses the container and the passage of fluid through the first fluid path is separately controllable from the passage of fluid through the second fluid path.Type: GrantFiled: October 1, 2019Date of Patent: May 9, 2023Assignee: Boston Scientific Scimed, Inc.Inventors: Andrew Pic, Matthew LaPlaca, Jennifer Golden, Shawn Ryan
-
Publication number: 20230060122Abstract: Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity.Type: ApplicationFiled: February 10, 2021Publication date: February 23, 2023Inventors: Robert Todd Striker, Nathan Joseph Wlodarchak, John Bruce Feltenberger, Jennifer Golden
-
Publication number: 20220251062Abstract: Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity.Type: ApplicationFiled: February 10, 2021Publication date: August 11, 2022Inventors: Robert Todd Striker, Nathan Joseph Wlodarchak, John Bruce Feltenberger, Jennifer Golden
-
Publication number: 20210162175Abstract: A medical device may comprise a handle and a flexible sheath extending from the handle. The sheath may include a first chamber configured to receive a first agent and a second chamber configured to receive a second agent. Each of the first chamber and the second chamber may be disposed in a distal portion of the sheath. The sheath may also include a first piston received within the first chamber and a second piston received within the second chamber and at least one actuation element configured to transmit a force from the handle to each of the first piston and the second piston. When the handle is in a first configuration, the first agent may be maintained within the first chamber and the second agent is maintained within the second chamber. When the handle is in a second configuration, the first agent may be released from the first chamber to mix with the second agent.Type: ApplicationFiled: December 2, 2020Publication date: June 3, 2021Applicant: Boston Scientific Scimed, Inc.Inventors: John Thomas Favreau, Stan Robert Gilbert, Jennifer Mague, Andrew Pic, Matthew LaPlaca, Jennifer Golden, Jennifer Whelehan, Travis Henchie
-
Publication number: 20200100986Abstract: A medical device including an application device with a first fluid path and a container movably attached to the application device. The container and the application device have a second fluid path therethrough, the container includes an inner chamber that is intermediate proximal and distal portions of the second fluid path, the inner chamber is fluidly isolated from the proximal portion of the second fluid path at a first position of the container, and the inner chamber is fluidly coupled to the proximal and distal portions of the second fluid path at a second position of the container. The first fluid path bypasses the container and the passage of fluid through the first fluid path is separately controllable from the passage of fluid through the second fluid path.Type: ApplicationFiled: October 1, 2019Publication date: April 2, 2020Applicant: Boston Scientific Scimed, Inc.Inventors: Andrew PIC, Matthew LaPLACA, Jennifer GOLDEN, Shawn RYAN
-
Patent number: 10532999Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: GrantFiled: October 1, 2018Date of Patent: January 14, 2020Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTEInventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Publication number: 20190270730Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: ApplicationFiled: October 1, 2018Publication date: September 5, 2019Inventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Patent number: 10087168Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: GrantFiled: February 27, 2017Date of Patent: October 2, 2018Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., SOUTHERN RESEARCH INSTITUTEInventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Publication number: 20170166557Abstract: The present technology relates to compounds and compositions of Formulas and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: ApplicationFiled: February 27, 2017Publication date: June 15, 2017Inventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Patent number: 9580393Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: GrantFiled: December 13, 2013Date of Patent: February 28, 2017Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., SOUTHERN RESEARCH INSTITUTEInventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Patent number: 9376452Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.Type: GrantFiled: May 15, 2014Date of Patent: June 28, 2016Assignee: ST. UNMInventors: Angela Wandinger-Ness, Larry Sklar, Jacob Agola, Zurab Surviladze, Jeffrey Aube, Jennifer Golden, Chad E. Schroeder, Denise S. Simpson
-
Publication number: 20150329499Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).Type: ApplicationFiled: December 13, 2013Publication date: November 19, 2015Inventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
-
Publication number: 20140248268Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Inventors: Angela Wandinger-Ness, Larry Sklar, Jacob Agola, Zurab Surviladze, Jeffrey Aube, Jennifer Golden, Chad E. Schroeder, Denise S. Simpson
-
Patent number: 8765803Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.Type: GrantFiled: February 24, 2012Date of Patent: July 1, 2014Assignees: STC.UNM, University of KansasInventors: Angela Wandinger-Ness, Larry Sklar, Jacob Agola, Zurab Surviladze, Jeffrey Aubé, Jennifer Golden, Chad E. Schroeder, Denise S. Simpson
-
Publication number: 20110225917Abstract: A method for making a decorative architectural element is disclosed, which includes the steps of designing a vacuum form mold forming a three dimensional decorative shape for the architectural element, cut a moldable plastic sheet in a size and shape to fit over the vacuum form mold, designing a color graphic, print the color graphic onto a vinyl wrap which corresponds in size and shape to fit over the vacuum form mold covered with the plastic sheet, vacuum forming the plastic sheet over the vacuum form mold and the vinyl wrap over the plastic sheet. The plastic sheet takes the shape of the vacuum form mold and the vinyl wrap adheres to the molded plastic sheet. The molded plastic sheet and the attached molded vinyl wrap are then removed from the vacuum mold. One arrangement includes the step of affixing the molded plastic sheet with the attached molded vinyl wrap to the architectural element.Type: ApplicationFiled: March 16, 2010Publication date: September 22, 2011Inventors: Jennifer Golden, Stephen J. Sexton
-
Publication number: 20110212940Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: February 25, 2011Publication date: September 1, 2011Applicant: EPIX PHARMACEUTICALS, INC.Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
-
Patent number: 7919519Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: GrantFiled: March 21, 2007Date of Patent: April 5, 2011Assignee: Epix Pharmaceuticals Inc.Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
-
Publication number: 20080027036Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: March 21, 2007Publication date: January 31, 2008Applicant: EPIX Delaware, Inc.Inventors: Roland Burli, Victor Cee, Jennifer Golden, Brian Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa Cheruku, Pini Orbach, Anurag Sharadendu, Robert Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang